Abstract
Public health indicators typically used for COVID-19 surveillance can be biased or lag changing community transmission patterns. The United States city of Chicago opportunistically investigated whether sentinel surveillance of recently symptomatic individuals receiving outpatient diagnostic testing for SARS-CoV-2 could accurately assess the instantaneous reproductive number R(t) and provide early warning of changes in transmission. Patients tested at community-based diagnostic testing sites between September 2020 and June 2021, and reporting symptom onset within four days preceding their test, formed the sentinel population. R(t) calculated from sentinel cases agreed well with R(t) from other indicators. Retrospectively, trends in sentinel cases did not precede trends in COVID-19 hospital admissions by any identifiable lead time. In deployment, sentinel surveillance held an operational recency advantage of nine days over hospital admissions. The promising performance of opportunistic sentinel surveillance suggests that deliberately designed outpatient sentinel surveillance would provide robust early warning of increasing transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RR was supported by a grant from NIGMS (T32 GM008449). TH and JG were supported by the Peterson Foundation Pandemic Response Policy Research Fund. JG was supported by the NIGMS MIDAS COVID-19 Urgent Grant Program (MIDASNI2020-4).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Northwestern University Institutional Review Board has ruled that this study does not constitute human subjects research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Restrictions apply to the availability of sentinel surveillance data and individual-level diagnostic tests from I-NEDSS, which contain identifiable private health information. Interested parties should contact CDPH or IDPH to inquire about access. Public data on cases, testing, ED visits, and hospital admissions are available from CDPH's Public Data Portal. All code used for data analysis is available at https://github.com/numalariamodeling/chicago_sentinel_surveillance.
https://data.cityofchicago.org/
https://github.com/numalariamodeling/chicago_sentinel_surveillance
